Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.36 |
| ▸ | RORC | P51449 | 11/20 | 0.35 |
| ▸ | PPARG | P37231 | 5/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693265 | 0.95 | KMT2A (0.47) | KMT2AKDM4EALDH1A1MAP2K1RORC | |
| SCHEMBL697251 | 0.81 | KMT2A (0.43) | KMT2AKDM4EALDH1A1MAP2K1RORC | |
| SCHEMBL2425927 | 0.78 | MAPK1 (0.55) | KMT2AALDH1A1MAP2K1MAPK1 | |
| SCHEMBL2052824 | 0.77 | KDM4E (0.47) | KMT2AKDM4EALDH1A1MAP2K1RORC | |
| SCHEMBL4342719 | 0.75 | PDE3B (0.48) | KMT2AKDM4EALDH1A1MAPK1 | |
| SCHEMBL21378233 | 0.72 | KMT2A (0.44) | KMT2AKDM4EALDH1A1RORCPPARG | |
| SCHEMBL13857265 | 0.68 | KDM4E (0.50) | KMT2AKDM4EALDH1A1MAP2K1CNR1 | |
| SCHEMBL693438 | 0.67 | KMT2A (0.46) | KMT2AKDM4EALDH1A1RORCPPARG | |
| SCHEMBL21810123 | 0.66 | SLC10A1 (0.38) | KMT2AKDM4EALDH1A1MAPK1 | |
| SCHEMBL9233695 | 0.66 | KDM4E (0.48) | KMT2AKDM4EALDH1A1MAP2K1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022057-B2 | MAPK/ERK kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-20 | — | — | US | claimed |
| EP-2227469-B9 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-09-10 | — | — | EP | disclosed |
| EP-2227469-B1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-01-08 | — | — | EP | disclosed |
| US-8022057-B2 | MAPK/ERK kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022057-B2 | MAPK/ERK kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022057-B2 | MAPK/ERK kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-20 | — | — | US | disclosed |
| EP-2227469-A1 | MAPK/ERK KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009064675-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064675-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-22 | — | — | WO | disclosed |
| US-20090124595-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-14 | — | — | US | disclosed |
| US-20090124595-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-14 | — | — | US | disclosed |
| US-20090124595-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124595-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | KMT2A 2404/4885KDM4E 2363/4885ALDH1A1 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.